Drug Profile
Forigerimod - ImmuPharma
Alternative Names: CEP-33457; IPP-201101; Lupuzor; peptide P140; Rigerimod; SyB 1001Latest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator CNRS
- Developer ImmuPharma
- Class Oligopeptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Systemic lupus erythematosus
- Phase II Chronic inflammatory demyelinating polyradiculoneuropathy
- Preclinical Asthma; Gout; Periodontitis
Most Recent Events
- 21 Mar 2023 ImmuPharma completes a phase I pharmacokinetics trial (In volunteers) in Whales and United Kingdom (IV, SC) (ISRCTN16878305)
- 28 Nov 2022 Phase-II clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (SC) (ImmuPharma pipeline, November 2022)
- 28 Nov 2022 Preclinical trials in Asthma in United Kingdom (SC) (ImmuPharma pipeline, November 2022)